JP2020527355A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527355A5
JP2020527355A5 JP2020502992A JP2020502992A JP2020527355A5 JP 2020527355 A5 JP2020527355 A5 JP 2020527355A5 JP 2020502992 A JP2020502992 A JP 2020502992A JP 2020502992 A JP2020502992 A JP 2020502992A JP 2020527355 A5 JP2020527355 A5 JP 2020527355A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
cdr2
cdr3
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020502992A
Other languages
English (en)
Japanese (ja)
Other versions
JP7690285B2 (ja
JP2020527355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042532 external-priority patent/WO2019018426A1/en
Publication of JP2020527355A publication Critical patent/JP2020527355A/ja
Publication of JP2020527355A5 publication Critical patent/JP2020527355A5/ja
Priority to JP2023065086A priority Critical patent/JP2023083385A/ja
Application granted granted Critical
Publication of JP7690285B2 publication Critical patent/JP7690285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020502992A 2017-07-17 2018-07-17 結合タンパク質1 Active JP7690285B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065086A JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質1

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762533546P 2017-07-17 2017-07-17
US62/533,546 2017-07-17
US201762596694P 2017-12-08 2017-12-08
US62/596,694 2017-12-08
PCT/US2018/042532 WO2019018426A1 (en) 2017-07-17 2018-07-17 BINDING PROTEINS 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065086A Division JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質1

Publications (3)

Publication Number Publication Date
JP2020527355A JP2020527355A (ja) 2020-09-10
JP2020527355A5 true JP2020527355A5 (https=) 2021-08-26
JP7690285B2 JP7690285B2 (ja) 2025-06-10

Family

ID=65015294

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502992A Active JP7690285B2 (ja) 2017-07-17 2018-07-17 結合タンパク質1
JP2023065086A Pending JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質1

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065086A Pending JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質1

Country Status (8)

Country Link
US (5) US20200216568A1 (https=)
EP (1) EP3655432A4 (https=)
JP (2) JP7690285B2 (https=)
CN (1) CN111094338A (https=)
AU (1) AU2018302110B2 (https=)
CA (2) CA3070252A1 (https=)
IL (1) IL272064A (https=)
WO (2) WO2019018426A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2019152806A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
CN116529266A (zh) 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
CN117295753A (zh) 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
AU2022228255A1 (en) 2021-03-03 2023-09-28 Yale University Compositions and methods for treating skeletal muscle disease
JP2024519169A (ja) * 2021-05-25 2024-05-08 トランスマブ・ピーティーワイ・リミテッド 改善された免疫グロブリンi
US20240226311A1 (en) * 2021-05-25 2024-07-11 Transmab Pty Ltd Improved immunoglobulin II
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
EP4448745A4 (en) * 2021-12-15 2025-12-24 Univ Indiana Trustees CELLULAR TARGETING COMPOSITIONS AND METHODS
US20230303719A1 (en) * 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023168401A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
AU2023338626A1 (en) 2022-09-09 2025-03-20 Yale University Proteolysis targeting antibodies and methods of use thereof
EP4642488A1 (en) 2022-12-27 2025-11-05 Yale University Antibody drug conjugates
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
EP4683674A1 (en) 2023-03-23 2026-01-28 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
CN121159711A (zh) * 2024-01-02 2025-12-19 河北神宇生物技术有限公司 一种提高adc药物疗效的重组蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615662D0 (en) 2006-08-07 2006-09-13 Affitech As Antibody
CA2907072A1 (en) * 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
AU2015204446A1 (en) * 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
WO2015192092A1 (en) * 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
WO2016033321A1 (en) 2014-08-28 2016-03-03 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody

Similar Documents

Publication Publication Date Title
JP2020527355A5 (https=)
JP2020502271A5 (https=)
JP2022101693A5 (https=)
JP2023548443A5 (https=)
JP2021524268A5 (https=)
JP2021508469A5 (https=)
JP2021534762A5 (https=)
JP2021527714A5 (https=)
JP2020501531A5 (https=)
RU2019143101A (ru) Новое анти-с-мет антитело и его применение
JP2013527761A5 (https=)
JP2018108081A5 (https=)
JP2021524267A5 (https=)
JP2017530722A5 (https=)
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2017529838A5 (https=)
JP2019513018A5 (https=)
JP2017535257A5 (https=)
JP2017506067A5 (https=)
RU2010141584A (ru) Антитело против csf-1r
JP2023543031A5 (https=)
FI3856775T3 (fi) Kimeerinen antigeenireseptori
JP2021515798A5 (https=)
JP2011207882A5 (https=)
JP2021508707A5 (https=)